Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), relating to its proposed acquisition by Harmony Biosciences Holdings, Inc. Under the terms of the tender offer, ZYNE shareholders are expected to receive $1.1059 in cash plus one non-tradeable CVR per share they own.